Biora Therapeutics Stock Extend Surge on FDA Feedback

Year-over-year, BIOR is down more than 86%

Fernanda Horner

Digital Content Manager

Jan 11, 2023 at 10:12 AM

BIOR

Biora Therapeutics Inc (NASDAQ:BIOR) is looking to extend yesterday's pop, last seen up 8.5% at $5.86. This bull gap comes after the U.S. Food and Drug Administration (FDA) provided feedback for its program targeting ulcerative colitis, with the company saying that it is on track to file plans to initiate clinical trials in the second quarter. Plus, Wainwright raised its price target to $65 from $6.

The security is fresh off a Jan. 6, record low of $1.95, but yesterday closed above the 40-day moving average for the first time since August. The shares are today trading at their highest level in more than one month. Year-over-year, though, BIOR Is down 86.8%.

Short sellers are already starting to hit the exits, with short interest down 9.4% in the last two reporting periods. Still the 11.73 million shares sold short account for 5.6% of BIOR's available float.

Follow @Schaeffers

You Don’t Need 25 Alerts -- You Need ONE You Can Trust!

That’s the idea behind Trade of the Week, Schaeffer’s newest trade alert.

Every Monday morning before the opening bell, you’ll receive a single, expertly researched trade recommendation -- built from the same proprietary research we’ve been using for over four decades.

It’s not just a signal.

It’s a plan designed for traders who are tired of jumping from alert to alert without ever finding their edge.

No juggling alerts. No switching directions mid-week. Just one clear, expertly researched trade idea -- delivered before the market even opens.

👉 JOIN RIGHT NOW FOR JUST $1 TO GET THE NEXT TRADE!